We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · September 23, 2020

Nab-Paclitaxel vs Paclitaxel in Patients With Platinum-Refractory Metastatic Urothelial Cancer

JAMA Oncology


Additional Info

JAMA Oncology
Efficacy and Safety of Nab-Paclitaxel vs Paclitaxel on Survival in Patients With Platinum-Refractory Metastatic Urothelial Cancer: The Canadian Cancer Trials Group BL.12 Randomized Clinical Trial
JAMA Oncol 2020 Sep 17;[EPub Ahead of Print], SS Sridhar, N Blais, B Tran, MN Reaume, SA North, MR Stockler, KN Chi, NE Fleshner, G Liu, JW Robinson, SD Mukherjee, Y Rahim, E Winquist, CM Booth, NT Nguyen, EK Beardsley, NS Alimohamed, GT McDonald, K Ding, WR Parulekar

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading